A paper written by University of Florida Computer & Information Science & Engineering, or CISE, Professor Sumit Kumar Jha, Ph ...
The startup is making solid-state transformers capable of intelligently aggregating power from a number of different sources ...
FOSDEM 2026 Amid growing interest in digital sovereignty and getting data out of the corporate cloud and into organizations' ownership, the Matrix open communication protocol is thriving. The project ...
Per the terms of the agreement, Novavax will receive an upfront payment of $30 million from Pfizer and is eligible to earn up to $500 million in potential development and commercial milestone payments ...
Novavax secures a non-exclusive licensing deal with Pfizer, validating Matrix-M's platform value and shifting NVAX toward a technology provider model. NVAX receives $30M upfront, a potential $500M in ...
Novavax NVAX announced a non-exclusive license agreement with Pfizer PFE, granting the latter access to its proprietary Matrix-M adjuvant technology for use in up to two disease areas. The ...
Novavax has agreed to a deal to let Pfizer use Matrix-M adjuvant in its products for an upfront payment of $30 million and up to another $500 million in milestone payments. The biotech company said ...
Pfizer is paying $30 million to use Novavax’s adjuvant technology to improve the efficacy of two of the Big Pharma’s vaccine programs. The tech, called Matrix-M, is designed to trigger an immune ...
As an entrepreneur, you’re likely seeking growth. Maybe you’re eyeing new products and services you could offer, or new customers who would love your brand if you entered their market. If you’re ...
(RTTNews) - Novavax, Inc. (NVAX) announced Tuesday progress on its collaboration and license agreement (CLA) with Sanofi SA (SNY) regarding Novavax's Matrix-M adjuvant. The companies have amended ...
Ambitious targets drive progress—but how do we know if a target is truly ambitious? This video explores how the FAB Matrix evaluates ambitiousness by comparing proposed targets to business-as-usual ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results